Skip to content
GLP-1 Scorecard
Menu
Graded #151

GOAL.MD

GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing

Visit GOAL.MDWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$179/mo
Tirzepatide
$249/mo (starting dose, compounded)
Coverage
All 50 states
Brand-name
Yes

Weigh GOAL.MD against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value64/100
Dose & formulation86/100
Clinical oversight68/100
Labs & monitoring53/100
Fulfillment77/100
Contract terms55/100

Strengths

  • Transparent dose-tiered pricing on brand pens
  • LegitScript Certified
  • Manual-renewal model — no surprise auto-billing
  • Free nutrition coach included
  • BBB A+ rating since 2021

Where it loses points

  • No named compounding pharmacy partner
  • Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
  • No URAC or PCAB pharmacy accreditation

Bottom line — Grade C

Best for: Shoppers who want manual-renewal billing with dose-tiered brand-name pricing transparency.

Ranked #151 of 499 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest GOAL.MD — the realistic shortlist.

The 19 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect GOAL.MD's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on GOAL.MD's site. Not medical advice; see our disclosure.

← Back to the scorecard